Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents

BACKGROUND: Grade 3 and 4 adverse events (AEs) during cycle 1 are traditionally used for dose escalation decisions in Phase I oncology trials. With molecularly targeted agents (MTAs), assessment of lower grade AEs and those in later cycles is considered increasingly relevant. METHODS: We conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jordan, Emma J., Spicer, James, Sarker, Debashis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188052/
https://www.ncbi.nlm.nih.gov/pubmed/30338038
http://dx.doi.org/10.18632/oncotarget.26104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188052/
https://www.ncbi.nlm.nih.gov/pubmed/30338038
http://dx.doi.org/10.18632/oncotarget.26104

Ejemplares similares